Merck Announces Second-Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Merck (MRK) to Acquire cCAM Biotherapeutics in ~$605M Deal
July 28, 2015 7:58 AM EDTMerck (NYSE: MRK) and cCAM Biotherapeutics announced that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies.
Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding stock of cCAM in exchange for an upfront payment of $95 million in cash. In addition, cCAM shareholders of record are eligible to receive a total of up to $510 million associated with the attainment of certain clinical development, regulatory and commercial... More
Merck (MRK) Tops Q2 EPS by 5c; Narrows and Raise FY15 EPS Outlook
July 28, 2015 7:02 AM EDTMerck (NYSE: MRK) reported Q2 EPS of $0.86, $0.05 better than the analyst estimate of $0.81. Revenue for the quarter came in at $9.8 billion versus the consensus estimate of $9.8 billion.
Merck sees FY2015 EPS of $3.45-$3.55, versus the consensus of $3.45.
Were investing resources... More
